SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3

Objective: To determine the efficacy and safety of sofosbuvir-velpatasvir combination therapy in treatment of chronic hepatitis C genotype 3. Study Design: Prospective cohort study. Place and Duration of Study: Department of Medicine, Combined Military Hospital Lahore, from Mar 2018 to Oct 201...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arif Qayyum Khan, Hala Mansoor, Samina Fida, Saba Saif, Javed Iqbal, Muhammad Siddique
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	hepatitis c sustained virological response sofosbuvir velpatasvir Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/2841f49f314e4c478be8efc7acad314a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2841f49f314e4c478be8efc7acad314a
record_format	dspace
spelling	oai:doaj.org-article:2841f49f314e4c478be8efc7acad314a2021-12-02T16:32:53ZSOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 30030-96482411-884210.51253/pafmj.v71i1.4339https://doaj.org/article/2841f49f314e4c478be8efc7acad314a2021-02-01T00:00:00Zhttps://pafmj.org/index.php/PAFMJ/article/view/4339https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To determine the efficacy and safety of sofosbuvir-velpatasvir combination therapy in treatment of chronic hepatitis C genotype 3. Study Design: Prospective cohort study. Place and Duration of Study: Department of Medicine, Combined Military Hospital Lahore, from Mar 2018 to Oct 2019. Methodology: Eighty eight consecutive patients, who were ≥18 years of age with chronic hepatitis C as confirmed by polymerase chain reaction were included in the study. Primary end point was sustained virological response at 12 week post-treatment. Patients with any of the following criteria at presentation were excluded from study: aspartate/alanine aminotransferase >10 times the upper limit of normal, total bilirubin twice the upper limit of normal, haemoglobin <8g/dL, platelet count <30,000/uL, albumin <2 g/dL and creatinine clearance of <60 mL/ min. Additional criteria for exclusion included patients who had co-infection with hepatitis B or human immune deficiency virus (HIV), significant cardiac or lung disease, porphyria, liver cirrhosis caused by non-HCV related causes or co-existent hepatocellular carcinoma. Results: Overall sustained virological response was achieved in 82 of 84 patients (97.6%). One of the patients with genotype 3 had detectable HCV RNA at end of treatment, which became undetectable at 12 weeks, post-treatment. 38 /38 (100%) patients without cirrhosis while 41/43 patients (95.3%) with compensated cirrhosis and 3/3 with decompensated cirrhosis achieved sustained virological response. Two (2.3%) patients had on-treatment virological failure. Four patients were lost to follow up. Conclusion: Treatment with sofosbuvir and velpatasvir is effective and well tolerated in patients with chronic hepatitis C, genotype 3.Arif Qayyum KhanHala MansoorSamina FidaSaba SaifJaved IqbalMuhammad SiddiqueArmy Medical College Rawalpindiarticlehepatitis csustained virological responsesofosbuvirvelpatasvirMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 71, Iss 1, Pp 122-28 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatitis c sustained virological response sofosbuvir velpatasvir Medicine R Medicine (General) R5-920
spellingShingle	hepatitis c sustained virological response sofosbuvir velpatasvir Medicine R Medicine (General) R5-920 Arif Qayyum Khan Hala Mansoor Samina Fida Saba Saif Javed Iqbal Muhammad Siddique SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3
description	Objective: To determine the efficacy and safety of sofosbuvir-velpatasvir combination therapy in treatment of chronic hepatitis C genotype 3. Study Design: Prospective cohort study. Place and Duration of Study: Department of Medicine, Combined Military Hospital Lahore, from Mar 2018 to Oct 2019. Methodology: Eighty eight consecutive patients, who were ≥18 years of age with chronic hepatitis C as confirmed by polymerase chain reaction were included in the study. Primary end point was sustained virological response at 12 week post-treatment. Patients with any of the following criteria at presentation were excluded from study: aspartate/alanine aminotransferase >10 times the upper limit of normal, total bilirubin twice the upper limit of normal, haemoglobin <8g/dL, platelet count <30,000/uL, albumin <2 g/dL and creatinine clearance of <60 mL/ min. Additional criteria for exclusion included patients who had co-infection with hepatitis B or human immune deficiency virus (HIV), significant cardiac or lung disease, porphyria, liver cirrhosis caused by non-HCV related causes or co-existent hepatocellular carcinoma. Results: Overall sustained virological response was achieved in 82 of 84 patients (97.6%). One of the patients with genotype 3 had detectable HCV RNA at end of treatment, which became undetectable at 12 weeks, post-treatment. 38 /38 (100%) patients without cirrhosis while 41/43 patients (95.3%) with compensated cirrhosis and 3/3 with decompensated cirrhosis achieved sustained virological response. Two (2.3%) patients had on-treatment virological failure. Four patients were lost to follow up. Conclusion: Treatment with sofosbuvir and velpatasvir is effective and well tolerated in patients with chronic hepatitis C, genotype 3.
format	article
author	Arif Qayyum Khan Hala Mansoor Samina Fida Saba Saif Javed Iqbal Muhammad Siddique
author_facet	Arif Qayyum Khan Hala Mansoor Samina Fida Saba Saif Javed Iqbal Muhammad Siddique
author_sort	Arif Qayyum Khan
title	SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3
title_short	SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3
title_full	SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3
title_fullStr	SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3
title_full_unstemmed	SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3
title_sort	sofosbuvir-velpatasvir therapy in the treatment of chronic hepatitis c genotype 3
publisher	Army Medical College Rawalpindi
publishDate	2021
url	https://doaj.org/article/2841f49f314e4c478be8efc7acad314a
work_keys_str_mv	AT arifqayyumkhan sofosbuvirvelpatasvirtherapyinthetreatmentofchronichepatitiscgenotype3 AT halamansoor sofosbuvirvelpatasvirtherapyinthetreatmentofchronichepatitiscgenotype3 AT saminafida sofosbuvirvelpatasvirtherapyinthetreatmentofchronichepatitiscgenotype3 AT sabasaif sofosbuvirvelpatasvirtherapyinthetreatmentofchronichepatitiscgenotype3 AT javediqbal sofosbuvirvelpatasvirtherapyinthetreatmentofchronichepatitiscgenotype3 AT muhammadsiddique sofosbuvirvelpatasvirtherapyinthetreatmentofchronichepatitiscgenotype3
_version_	1718383798658269184

SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3

Ejemplares similares